Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
Open Access
- 11 September 2023
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1268402
Abstract
Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?Keywords
This publication has 7 references indexed in Scilit:
- Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint InhibitorsJournal of the Endocrine Society, 2021
- Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapyEndocrine, 2021
- A guide to cancer immunotherapy: from T cell basic science to clinical practiceNature Reviews Immunology, 2020
- Endocrine Toxicity of Cancer Immunotherapy Targeting Immune CheckpointsEndocrine Reviews, 2018
- High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanomaCancer, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathiesNature Reviews Endocrinology, 2017